Geron (GERN) Finished Goods (2024)

Geron's (GERN) quarterly Finished Goods came in at $3.7 million in Q4 2024, up 328.23% quarter-over-quarter from $868000.0 in Q3 2024.

Analysis

Geron (GERN) Finished Goods (2024) Analysis & Trends

Geron has disclosed Finished Goods across 1 years of filings, most recently posting $3.7 million for Q4 2024.

In Q4 2024, Finished Goods changed N/A year-over-year to $3.7 million; the TTM figure through Dec 2024 stood at $3.7 million (changed N/A YoY), while the FY2024 annual figure was $3.7 million, changed N/A from the prior year.
Finished Goods came in at $3.7 million for Q4 2024 at Geron, up from $868000.0 in the prior quarter.
In the past five years, Finished Goods ranged from a high of $3.7 million in Q4 2024 to a low of $774000.0 in Q2 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn
10	Geron	914.60 Mn	613.75 Mn	-

Historic Data

Download Data